Background Visceral leishmaniasis caused by the protozoan Leishmania infantum is a zoonotic, life threatening parasitic disease. Domestic dogs are the main peridomestic reservoir, and allopurinol is the most frequently used drug for the control of infection, alone or in combination with other drugs. Resistance of Leishmania strains from dogs to allopurinol has not been described before in clinical studies. Methodology/Principal Findings Following our observation of clinical disease relapse in dogs under allopurinol treatment, we tested susceptibility to allopurinol of L. infantum isolated from groups of dogs pre-treatment, treated in remission, and with disease relapse during treatment. Promastigote isolates obtained from four treated relapsed dogs (TR group) showed an average half maximal inhibitory concentration (IC50) of 996 μg/mL. A significantly lower IC50 (P = 0.01) was found for isolates from ten dogs before treatment (NT group, 200 μg/mL), as well as for five isolates obtained from treated dogs in remission (TA group, 268 μg/mL). Axenic amastigotes produced from isolates of the TR group also showed significantly higher (P = 0.002) IC50 compared to the NT group (1678 and 671 μg/mL, respectively). The lower sensitivity of intracellular amastigotes from the TR group relative to those from the NT group (P = 0.002) was confirmed using an infected macrophage model (6.3% and 20% growth inhibition, respectively at 300 μg/mL allopurinol). Conclusions This is the first study to demonstrate allopurinol resistance in L. infantum and to associate it with disease relapse in the canine host. These findings are of concern as allopurinol is the main drug used for long term control of the disease in dogs, and resistant L. infantum strains may enhance uncontrolled transmission to humans and to other dogs.
References
[1]
World Health Organization. Control of the Leishmaniases, Report of a WHO expert committee. World Health Organ Tech Rep Ser. 2010;949: 1–186.
[2]
Moreno J, Alvar J. Canine leishmaniasis: epidemiological risk and the experimental model. Trends Parasitol. 2002;18: 399–405. pmid:12377257 doi: 10.1016/s1471-4922(02)02347-4
[3]
Sivera F, Andrés M, Carmona L, Kydd AS, Moi J, Seth R, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis. 2014;73: 328–335. doi: 10.1136/annrheumdis-2013-203325. pmid:23868909
Baneth G, Shaw SE. Chemotherapy of canine leishmaniosis. Vet Parasitol. 2002;106: 315–324. pmid:12079737 doi: 10.1016/s0304-4017(02)00115-2
[6]
Chawla B, Madhubala R. Drug targets in Leishmania. J Parasit Dis. 2010;34: 1–13. doi: 10.1007/s12639-010-0006-3. pmid:21526026
[7]
Bala？a-Fouce R, Requera RM, Cubría JC, Ordó？ez D. The pharmacology of leishmaniasis. Gen Pharmacol. 1998;30: 435–443. pmid:9580315 doi: 10.1016/s0306-3623(97)00268-1
[8]
Solano-Gallego L, Miró G, Koutinas A, Cardoso L, Pennisi MG, Ferrer L, et al. The LeishVet Group. LeishVet guidelines for the practical management of canine leishmaniosis. Parasit Vectors. 2011; 4: 86. doi: 10.1186/1756-3305-4-86. pmid:21599936
[9]
Manna L, Corso R, Galiero G, Cerrone A, Muzj P, Gravino AE. Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol. Parasit Vectors. 2015;8: 289. doi: 10.1186/s13071-015-0896-0. pmid:26017164
[10]
Pasa S, Toz SO, Voyvoda H, Ozbel Y. Clinical and serological follow-up in dogs with visceral leishmaniosis treated with allopurinol and sodium stibogluconate. Vet Parasitol. 2005;128: 243–249. pmid:15740861 doi: 10.1016/j.vetpar.2004.12.002
[11]
Miró G, Gálvez R, Fraile C, Descalzo MA, Molina R. Infectivity to Phlebotomus perniciosus of dogs naturally parasitized with Leishmania infantum after different treatments. Parasit Vectors. 2011;4: 52 doi: 10.1186/1756-3305-4-52. pmid:21489241
[12]
Koutinas AF. Saridomichelakis MN. Mylonakis ME. Leontides L. Polizopoulou Z. Billinis C, et al. A randomised, blinded, placebo-controlled clinical trial with allopurinol in canine leishmaniosis. Vet Parasitol. 2001;98: 247–261. pmid:11423183 doi: 10.1016/s0304-4017(01)00399-5
[13]
Miró G, Cardoso L, Pennisi MG, Oliva G, Baneth G. Canine leishmaniosis-new concepts and insights on an expanding zoonosis: part two. Trends Parasitol. 2008;24: 371–377. doi: 10.1016/j.pt.2008.05.003. pmid:18603476
[14]
Ginel PJ, Lucena R, López R, Molleda JM. Use of allopurinol for maintenance of remission in dogs with leishmaniasis. J Small Anim Practice. 1998;39:271–274. doi: 10.1111/j.1748-5827.1998.tb03649.x
[15]
Cavaliero T, Arnold P, Mathis A, Glaus T, Hofmann-Lehmann R, Deplazes P. Clinical, serologic, and parasitologic follow-up after long-term allopurinol therapy of dogs naturally infected with Leishmania infantum. J Vet Intern Med. 1999;13: 330–334. pmid:10449224 doi: 10.1892/0891-6640(1999)013<0330:csapfu>2.3.co;2
[16]
Slappendel RJ, Teske E. The effect of intravenous or subcutaneous administration of meglumine antimonite (Glucantime) in dogs with leishmaniasis–A randomized clinical trial. Vet Q. 1997;19:10–13. pmid:9225422 doi: 10.1080/01652176.1997.9694729
[17]
Manna L, Reale S, Vitale F, Picillo E, Pavone LM, Gravino AE. Real-time PCR assay in Leishmania-infected dogs treated with meglumine antimoniate and allopurinol. Vet J. 2007;177: 279–282. pmid:17553711 doi: 10.1016/j.tvjl.2007.04.013
[18]
Torres M, Bardagí M, Roura X, Zanna G, Ravera I, Ferrer L. Long term follow-up of dogs diagnosed with leishmaniosis (clinical stage II) and treated with meglumine antimoniate and allopurinol. Vet J. 2011;188: 346–351. doi: 10.1016/j.tvjl.2010.05.025. pmid:20594876
[19]
Ubeda JM, Légaré D, Raymond F, Ouameur AA, Boisvert S, Rigault P. et al. Modulation of gene expression in drug resistant Leishmania is associated with gene amplification, gene deletion and chromosome aneuploidy. Genome Biol. 2008;9: R115. doi: 10.1186/gb-2008-9-7-r115. pmid:18638379
[20]
do Monte-Neto RL, Coelho AC, Raymond F, Légaré D, Corbeil J, Melo MN, et al. Gene expression profiling and molecular characterization of antimony resistance in Leishmania amazonensis. PLoS Negl Trop Dis. 2011: 5: e1167. doi: 10.1371/journal.pntd.0001167. pmid:21629719
[21]
A？t-Oudhia K, Gazanion E, Vergnes B, Oury B, Sereno D. Leishmania antimony resistance: what we know what we can learn from the field. Parasitol Res. 2011;109: 1225–1232. doi: 10.1007/s00436-011-2555-5. pmid:21800124
[22]
Purkait B, Kumar A, Nandi N, Sardar AH, Das S, Kumar S, et al. Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani. Antimicrob. Agents Chemother. 2012;56: 1031–1041. doi: 10.1128/AAC.00030-11. pmid:22123699
[23]
Coelho AC, Boisvert S, Mukherjee A, Leprohon P, Corbeil J. Ouellette M. Multiple mutations in heterogeneous miltefosine-resistant Leishmania major population as determined by whole genome sequencing. PLoS Negl Trop Dis. 2012;6: e1512. doi: 10.1371/journal.pntd.0001512. pmid:22348164
[24]
Cojean S, Houzé S, Haouchine D, Huteau F, Lariven S, Hubert V, et al. Leishmania resistance to miltefosine associated with genetic marker. Emerg Infect Dis. 2012;18: 704–706. doi: 10.3201/eid1804.110841. pmid:22469394
[25]
Gramiccia M, Gradoni L, Orsini S. Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment. Ann Trop Med Parasitol. 1992;86: 613–620. pmid:1304703
[26]
Carrió J, Portús M. In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during In vitro or in vivo passages but is modified after host treatment with meglumine antimoniate. BMC Pharmacology. 2002;2: 2–11.
[27]
A？t-Oudhia K, Gazanion E, Sereno D, Oury B, Dedet JP, Pratlong F, et al. In vitro susceptibility to antimonials and amphotericin B of Leishmania infantum strains isolated from dogs in a region lacking drug selection pressure. Vet Parasitol. 2012;187: 386–393. doi: 10.1016/j.vetpar.2012.01.034. pmid:22349936
[28]
Manna L, Vitale F, Reale S, Picillo E, Neglia G, Vescio F, et al. Study of efficacy of miltefosine and allopurinol in dogs with leishmaniosis. Vet J. 2009;182: 441–445. doi: 10.1016/j.tvjl.2008.08.009. pmid:18818112
[29]
Baneth G, Dank G, Keren-Kornblatt E, Sekeles E, Adini I, Eisenberger CL, et al. Emergence of visceral leishmaniasis in central Israel. Am J Trop Med Hyg. 1998;59: 722–725. pmid:9840588
[30]
Nicolas L, Milon G. Prina E. Rapid differentiation of Old World Leishmania species by LightCycler polymerase chain reaction and melting curve analysis. J Microbiol. methods 2002;51: 295–299. pmid:12223289 doi: 10.1016/s0167-7012(02)00099-4
[31]
Schnur LF, Jacobson RL. Appendix III. Parasitological techniques. In: Peters W. Killick-Kendrick R, editors. The Leishmaniases in Biology and Medicine. London: Academic Press Inc.; 1987. pp. 499–541.
[32]
Shimony O, Jaffe CL. Rapid fluorescent assay for screening drugs on Leishmania amastigotes. J Microbiol Methods. 2008;75: 196–200. doi: 10.1016/j.mimet.2008.05.026. pmid:18573286
[33]
Sereno D, Lemesre JL. Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents. Antimicrob Agents Chemother. 1997;41: 972–976. pmid:9145854
[34]
el Tai NO, Osman OF, el Fari M, Presber W, Sch？nian G. Genetic heterogeneity of ribosomal internal transcribed spacer in clinical samples of Leishmania donovani spotted on filter paper as revealed by single-strand conformation polymorphisms and sequencing. Trans R Soc Trop Med Hyg. 2000;94: 575–579. pmid:11132393 doi: 10.1016/s0035-9203(00)90093-2
[35]
Strauss-Ayali D, Baneth G, Jaffe CL. Splenic immune responses during canine visceral leishmaniasis. Vet Res. 2007;38: 547–564. pmid:17540157 doi: 10.1051/vetres:2007015
[36]
Maia C, Nunes M, Marques M, Henriques S, Rol？o N, Campino L. In vitro drug susceptibility of Leishmania infantum isolated from humans and dogs. Exp Parasitol. 2013;135: 36–41. doi: 10.1016/j.exppara.2013.05.015. pmid:23747751
[37]
Quinnell RJ, Courtenay O. Transmission, reservoir hosts and control of zoonotic visceral leishmaniasis. Parasitology. 2009;136: 1915–1934. doi: 10.1017/S0031182009991156. pmid:19835643
